Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell™) Across Multiple Ischemic and Vascular Indications Simultaneously Read More
Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company Read More
Hemostemix’s Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical Trial Read More
Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company Read More
Hemostemix Hiring 4 New Biotechnologists in Montreal and Appling for Grants to Fund up to 75% of 5-Year Costs Read More
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences Read More
Hemostemix Oversubscribed, Closing $2,700,000 Private Placement and Settles $400,000 of Debt at $0.20 per Share Read More
Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board Read More
Hemostemix Submits its Retrospective Heart Study to Leading Stem Cell Journal and has Prepared its CLI Phase II Clinical Trial Manuscript for Peer Review Read More
Hemostemix’s Announces its 10th Publication: A Molecular Strategy for the Treatment of Heart Failure: Response to Biocardia’s Cardiamp Heart Failure Trial Read More
Hemostemix’s VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments! Read More
Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01 Read More
Cells: Hemostemix ACP-01 and NCP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants Read More
Hemostemix Offers up to 500 6% Convertible Debentures, Convertible into an ACP-01 Therapeutic Production Slot that is Subject to Compassionate Exemption from Regulatory Approval Read More
Hemostemix and FireFly Neuroscience’s Brain Network Analytics (BNA™) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01 Read More
Investor Relations Hemostemix and CytoImmune Amend Manufacturing Agreement to Accelerate Global Scale-Up Read More
Hemostemix’ Second Round Interviews with Executive Vice President Business Development Candidates Read More
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to its Scientific Advisory Board Read More
Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000 Read More
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board Read More
Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to its Scientific Advisory Board Read More
Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments Read More
Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials Read More
HEMOSTEMIX ANNOUNCES THE FIRST TRANCHE CLOSING OF $1.8M OF ITS RECENTLY ANNOUNCED PRIVATE PLACEMENT Read More
Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications Read More
HEMOSTEMIX’S SOCIAL MEDIA AWARENESS OF “YOUR FOUNTAIN OF YOUTH” (TM) REGENERATIVE MEDICINE TREATMENTS IS GAINING TRACTION Read More
Hemostemix Announces Letter of Commitment, Non-dilutive Funding Structure and $250,000 of Funding by the McGill University Health Centre Foundation Read More
Hemostemix PR Inc. Congratulates Luis Muñoz Marín International Airport on Achieving CEIV Pharma Certification Read More
Hemostemix’s 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease Read More
HEMOSTEMIX ANNOUNCES ACP-01 TREATMENT-PURCHASE AVAILABLE WITH SOCIAL MEDIA CAMPAIGN UNDERWAY Read More
Hemostemix Announces the Incorporation of PreCerv Inc. and a Global Field of Use License to NCP-01 Read More
Investor Relations Hemostemix Announces the Incorporation of Hemostemix PR Inc: 50% reimbursement of R&D expenses in cash Read More
Investor Relations Hemostemix Presents at Puerto Rico Investor Summits: Showcasing Global Scale-Up Strategy and Economic Impact Read More
